Research graph

References

References from Cellular immune responses in transplantation‐associated chronic viral infections. Local targets link to admitted publications; unresolved targets remain external evidence.

10.1084/jem.145.3.644

10.1084/jem.145.3.644 · External reference

10.1146/annurev.immunol.16.1.323

10.1146/annurev.immunol.16.1.323 · External reference

10.1084/jem.189.6.991

10.1084/jem.189.6.991 · External reference

10.1126/science.283.5403.857

10.1126/science.283.5403.857 · External reference

10.1128/jvi.71.4.3120-3128.1997

10.1128/jvi.71.4.3120-3128.1997 · External reference

CD4+ T cells are required to sustain CD8+ cytotoxic T‐cell responses during chronic viral infection

10.1128/jvi.68.12.8056-8063.1994 · 1994 · External reference

10.1084/jem.188.12.2205

10.1084/jem.188.12.2205 · External reference

10.1097/00000441-199305000-00005

10.1097/00000441-199305000-00005 · External reference

Cytomegalovirus infection following stem cell transplantation

1999 · External reference

10.1128/cmr.13.1.83-121.2000

10.1128/cmr.13.1.83-121.2000 · External reference

10.1093/clinids/10.supplement_3.s460

10.1093/clinids/10.supplement_3.s460 · External reference

10.1128/jvi.55.2.264-273.1985

10.1128/jvi.55.2.264-273.1985 · External reference

CD8‐positive T lymphocytes specific for murine cytomegalovirus immediate‐early antigens mediate protective immunity

10.1128/jvi.61.10.3102-3108.1987 · 1987 · External reference

10.1128/jvi.65.7.3641-3646.1991

10.1128/jvi.65.7.3641-3646.1991 · External reference

10.1016/s0167-5699(97)80017-5

10.1016/s0167-5699(97)80017-5 · External reference

10.1056/nejm198207013070102

10.1056/nejm198207013070102 · External reference

10.1093/clinids/6.2.156

10.1093/clinids/6.2.156 · External reference

10.1182/blood.v78.5.1373.1373

10.1182/blood.v78.5.1373.1373 · External reference

Recovery of HLA‐restricted cytomegalovirus‐specific T‐cell responses after allogeneic bone marrow transplant: correlation with cytomegalovirus disease and effect of ganciclovir prophylaxis

10.1182/blood.v83.7.1971.1971 · 1994 · External reference

Cytomegalovirus‐specific T‐cell immunity in recipients of autologous peripheral blood stem cell or bone marrow transplants

10.1182/blood.v89.10.3873 · 1997 · External reference

10.1086/314879

10.1086/314879 · External reference

10.1126/science.279.5359.2103

10.1126/science.279.5359.2103 · External reference

10.1097/00007890-200006150-00006

10.1097/00007890-200006150-00006 · External reference

10.1097/00007890-200006150-00005

10.1097/00007890-200006150-00005 · External reference

10.1097/00007890-200005150-00030

10.1097/00007890-200005150-00030 · External reference

10.1099/0022-1317-79-9-2099

10.1099/0022-1317-79-9-2099 · External reference

10.1038/nm0898-953

10.1038/nm0898-953 · External reference

10.1097/00042560-199904150-00016

10.1097/00042560-199904150-00016 · External reference

10.1002/(sici)1096-9071(199606)49:2<124::aid-jmv9>3.0.co;2-7

10.1002/(sici)1096-9071(199606)49:2<124::aid-jmv9>3.0.co;2-7 · External reference

10.1086/315445

10.1086/315445 · External reference

10.1126/science.280.5361.248

10.1126/science.280.5361.248 · External reference

Human cytomegalovirus replication and modulation of apoptosis in astrocytes

1998 · External reference

10.4049/jimmunol.164.2.926

10.4049/jimmunol.164.2.926 · External reference

Cytomegalovirus infection of peripheral blood mononuclear cells. Effects on interleukin‐1 and 2 production and responsiveness

10.1128/jvi.62.10.3603-3607.1988 · 1988 · External reference

10.1093/infdis/153.6.1084

10.1093/infdis/153.6.1084 · External reference

Human cytomegalovirus US3 impairs transport and maturation of major histocompatibility complex class I heavy chains

10.1073/pnas.93.21.11327 · 1996 · External reference

Human cytomegalovirus down‐regulates HLA class I expression by reducing the stability of class I H chains

10.4049/jimmunol.151.9.4455 · 1993 · External reference

10.1073/pnas.93.20.10990

10.1073/pnas.93.20.10990 · External reference

10.1038/384432a0

10.1038/384432a0 · External reference

10.1016/s0092-8674(00)81054-5

10.1016/s0092-8674(00)81054-5 · External reference

10.1038/386514a0

10.1038/386514a0 · External reference

10.1038/386510a0

10.1038/386510a0 · External reference

10.1006/cimm.1998.1424

10.1006/cimm.1998.1424 · External reference

10.1093/clinids/12.supplement_7.s754

10.1093/clinids/12.supplement_7.s754 · External reference

10.7326/0003-4819-114-7-525

10.7326/0003-4819-114-7-525 · External reference

Multicenter trial of Towne strain attenuated virus vaccine in seronegative renal transplant recipients

1994 · External reference

10.1093/clinids/12.supplement_7.s827

10.1093/clinids/12.supplement_7.s827 · External reference

10.1089/vim.2000.13.49

10.1089/vim.2000.13.49 · External reference

10.1016/s0002-8703(99)70281-4

10.1016/s0002-8703(99)70281-4 · External reference

10.1016/s0264-410x(98)00145-5

10.1016/s0264-410x(98)00145-5 · External reference

Studies evaluating high‐dose acyclovir, intravenous immune globulin, and cytomegalovirus hyperimmunoglobulin for prophylaxis against cytomegalovirus in kidney transplant recipients

10.1177/106002809603001215 · 1996 · External reference

10.1093/clinids/12.supplement_7.s839

10.1093/clinids/12.supplement_7.s839 · External reference

10.1097/00007890-198908000-00016

10.1097/00007890-198908000-00016 · External reference

Meta‐analysis of CMVIG studies for the prevention and treatment of CMV infection in transplant patients

1996 · External reference

10.1084/jem.165.3.650

10.1084/jem.165.3.650 · External reference

Adoptive immunotherapy of murine cytomegalovirus adrenalitis in the immunocompromised host. CD4‐helper‐independent antiviral function of CD8‐positive memory T lymphocytes derived from latently infected donors

10.1128/jvi.62.3.1061-1065.1988 · 1988 · External reference

10.1128/jvi.72.3.1797-1804.1998

10.1128/jvi.72.3.1797-1804.1998 · External reference

10.1056/nejm199510193331603

10.1056/nejm199510193331603 · External reference

10.1126/science.1352912

10.1126/science.1352912 · External reference

10.1126/science.285.5427.546

10.1126/science.285.5427.546 · External reference

Epstein‐Barr virus associated B cell lymphoproliferative disorders following bone marrow transplantation

10.1182/blood.v71.5.1234.1234 · 1988 · External reference

10.1111/j.1365-2559.1992.tb01007.x

10.1111/j.1365-2559.1992.tb01007.x · External reference

10.1182/blood.v72.2.520.520

10.1182/blood.v72.2.520.520 · External reference

Risk factors for developing EBV‐related B cell lymphoproliferative disorders (BLPD) after non‐HLA‐identical BMT in children

1996 · External reference

10.1182/blood.v87.6.2594.bloodjournal8762594

10.1182/blood.v87.6.2594.bloodjournal8762594 · External reference

10.1128/cmr.10.1.86

10.1128/cmr.10.1.86 · External reference

10.1146/annurev.immunol.15.1.405

10.1146/annurev.immunol.15.1.405 · External reference

Antigen‐driven expansion and contraction of CD8+‐activated T cells in primary EBV infection

10.4049/jimmunol.163.10.5735 · 1999 · External reference

10.1084/jem.185.9.1605

10.1084/jem.185.9.1605 · External reference

10.1084/jem.187.9.1395

10.1084/jem.187.9.1395 · External reference

A re‐evaluation of the frequency of CD8+ T cells specific for EBV in healthy virus carriers

10.4049/jimmunol.162.3.1827 · 1999 · External reference

10.1038/nm0896-906

10.1038/nm0896-906 · External reference

10.1172/jci4225

10.1172/jci4225 · External reference

10.1007/978-3-642-72045-1_8

10.1007/978-3-642-72045-1_8 · External reference

10.1016/s1074-7613(00)80622-6

10.1016/s1074-7613(00)80622-6 · External reference

Suppression of c‐Myc‐induced apoptosis by the Epstein‐Barr virus gene product BHRF1

10.1128/jvi.72.10.8392-8395.1998 · 1998 · External reference

10.1128/jvi.71.10.7509-7517.1997

10.1128/jvi.71.10.7509-7517.1997 · External reference

10.1097/00007890-199812270-00001

10.1097/00007890-199812270-00001 · External reference

10.1002/(sici)1097-0215(19961009)68:2<251::aid-ijc19>3.0.co;2-d

10.1002/(sici)1097-0215(19961009)68:2<251::aid-ijc19>3.0.co;2-d · External reference

10.1038/375685a0

10.1038/375685a0 · External reference

10.1128/jvi.71.11.8340-8346.1997

10.1128/jvi.71.11.8340-8346.1997 · External reference

10.1056/nejm199404283301703

10.1056/nejm199404283301703 · External reference

10.1056/nejm199409083311017

10.1056/nejm199409083311017 · External reference

10.1038/nm0596-551

10.1038/nm0596-551 · External reference

Infusion of cytotoxic T cells for the prevention and treatment of Epstein‐Barr virus‐induced lymphoma in allogeneic transplant recipients

10.1182/blood.v92.5.1549.417k32_1549_1555 · 1998 · External reference

Epstein‐Barr virus (EBV) load in bone marrow transplant recipients at risk to develop post transplant lymphoproliferative disease: prophylactic infusion of EBV‐specific cytotoxic T cells

10.1182/blood.v95.3.807.003k24_807_814 · 2000 · External reference

Epstein‐Barr virus (EBV)‐specific cytotoxic T lymphocytes for the treatment of patients with EBV‐positive relapsed Hodgkin's disease

10.1182/blood.v91.8.2925.2925_2925_2934 · 1998 · External reference

10.1086/515290

10.1086/515290 · External reference

Mig., the monokine induced by interferon‐gamma, promotes tumor necrosis in vivo

10.1182/blood.v89.8.2635 · 1997 · External reference

Simultaneous ex vivo expansion of cytomegalovirus and Epstein‐Barr virus‐specific cytotoxic T lymphocytes using B‐lymphoblastoid cell lines expressing cytomegalovirus pp65

10.1182/blood.v94.9.3242 · 1999 · External reference

10.1089/10430340050057521

10.1089/10430340050057521 · External reference

Unresolved reference

2000 · External reference

10.1128/jvi.74.2.914-922.2000

10.1128/jvi.74.2.914-922.2000 · External reference

10.1023/a:1006681312249

10.1023/a:1006681312249 · External reference

Induction of Epstein‐Barr virus‐specific cytotoxic T‐lymphocyte responses using dendritic cells pulsed with EBNA‐3A peptides or UV‐inactivated, recombinant EBNA‐3A vaccinia virus

10.1182/blood.v94.4.1372 · 1999 · External reference

Mature dendritic cells pulsed with freeze‐thaw cell lysates define an effective in vitro vaccine designed to elicit EBV‐specific CD4+ and CD8+ T lymphocyte responses

10.1182/blood.v96.5.1857 · 2000 · External reference